ShenZhen Cell Valley has the ability to standardize, standardize and industrialize the production of GMP grade CAR-T and other cell products, and has established production lines for CAR-T, CAR-NK, CAR-M, astroglia and other cell products, as well as production lines for genetic engineering antibody, cytokine, viral vector and other drugs.
Shenzhen Cell Valley Biopharmaceutical Co., Ltd. is a comprehensive one-stop outsourcing service provider in China focused on the cell and gene therapy industry. It is also one of the first CRO/CDMO companies in the country to possess GMP industrial production capabilities for clinical-grade retroviral vectors . The company is a major public technical service platform construction project for CRO/CDMO in Shenzhen and is included among the city's latest announced "20+8" strategic emerging industry projects.Shenzhen Cell Valley has the capability for standardized and industrialized production of GMP-grade cell products such as CAR-T cells. Its primary production lines include those for various cell products like CAR-T, CAR-NK, CAR-M, γδT, TIL, and TCR-T. Additionally, the company operates production lines for various viral vectors, including RVV, LVV, non-viral vectors, and AAV, as well as for cellular raw materials used in producing therapeutics such as exosomes, genetically engineered antibodies, cytokines, oncolytic viruses, and vaccines.